In addition, the FDA denied full approval for andexanet alfa (Andexxa) a month after an advisory committee highlighted uncertainties about which dose and in which patients it could best be used.

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.